BackAvecho Biotechnology Limited Overview

Avecho Biotechnology Limited Profit Margin

Avecho Biotechnology Limited (AVE.AX) has a profit margin of -343.94%, below the Healthcare sector average of 17.63%.

Get informed when a big investor buys or sells

+ Follow

Quarterly Profit Margin

-3227.48%
↓ 575.50% YoY

As of Jun 2026

Annual Profit Margin (TTM)

-343.94%
↑ 44.57% YoY

Trailing 12 months ending Jun 2026

Average Profit Margin (Comparison Companies)

Loading

Profit Margin History

Loading

Profit Margin Comparison

Loading

Annual Profit Margin Growth Rate (%)

Loading

Avecho Biotechnology Limited (AVE.AX) FAQ

Avecho Biotechnology Limited posts a profit margin of -343.94% as of June 2026. That compares with -620.53% in the prior-year period — up 44.6% year over year. That is below the Healthcare sector average of 17.63%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Avecho Biotechnology Limited's profit margin was -620.53%. The latest reading is -343.94% — a 44.6% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 17.63% is typical. Avecho Biotechnology Limited's -343.94% is lower that level. That is roughly 2051.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Avecho Biotechnology Limited's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -343.94% as of June 2026; use YoY and peer views to separate noise from signal.

Context for AVE.AX's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 17.63%), and (3) consistency with growth and profitability. This page covers the first two; Avecho Biotechnology Limited's other metric pages and overview cover the third.